Browse the evidence

Sodium bicarbonate ingestion increased peak power in the second set of the bench press exercise (g: 0.19; p = 0.03).

Sodium bicarbonate may enhance peak power output during resistance training.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) help manage type 2 diabetes mellitus (T2DM) by controlling blood sugar and promoting weight loss.

GLP-1RAs can be considered as a treatment option for patients with T2DM who need to manage blood sugar and weight.

A dietary score derived from 18 food groups is inversely associated with coronary heart disease (CHD) mortality, with a hazard ratio of 0.73.

Practitioners should consider dietary patterns that align with a Mediterranean diet to reduce heart disease risk.

More participants became pregnant in the low-volume HIT (LV-HIT) group than in the control group.

This indicates that low-volume HIT may have a positive effect on fertility in women with PCOS.

GLP-1 receptor agonists (GLP-1RAs) have transformed the management of obesity and provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control.

Practitioners can consider GLP-1RAs as effective options for managing obesity and glycemic control in patients.

After 5 weeks of a very low-calorie ketogenic diet (VLCKD), patients with Cushing's disease (CD) experienced a significant decrease in BMI (p=0.002), waist circumference (WC) (p=0.024), systolic (p=0.015) and diastolic blood pressure (p=0.005), ACTH (p=0.026), cortisone (p=0.025), total (p=0.006) and LDL cholesterol (p=0.017), triglycerides (p=0.016), alkaline phosphatase (p=0.008) and a significant increase in HDL cholesterol (p=0.017), vitamin D (p=0.015) and oral disposition index (Dio)(p=0.004).

Implementing a VLCKD may significantly improve metabolic health in patients with Cushing's disease.

A significant decrease in BMI (p=0.003), waist circumference (p=0.002), systolic (p=0.025) and diastolic blood pressure (p=0.007) and total cholesterol (p=0.026) and increase in HDL cholesterol (p=0.001) and oral disposition index (Dio)(p<0.001) was observed in controls after the diet.

A ketogenic diet may also benefit metabolic health in individuals without Cushing's disease.

The study confirms that a ketogenic diet is effective in improving metabolic disorders and can be combined with conventional therapy for Cushing's disease.

Combining a ketogenic diet with standard treatment may enhance metabolic outcomes in Cushing's disease patients.

Glucagon-like peptide-1 (GLP-1) agonists lead to greater weight loss in clinical trials and real-world settings than orlistat.

GLP-1 agonists may be a more effective pharmacological option for weight management in patients with obesity and inflammatory skin conditions.

GLP-1 receptor agonist patients experienced greater weight loss (7.8 kg) compared to controls (0.5 kg), with statistical significance (p<0.001).

Weight management strategies may be more effective in patients using GLP-1 receptor agonists.

Preoperative weight loss significantly improves long-term weight loss outcomes.

Encouraging preoperative weight loss may enhance surgical outcomes for patients.

AOM-naïve patients experienced superior weight loss outcomes with semaglutide compared to non-AOM-naïve patients at 3, 6, 9, and 12 months.

Practitioners should consider that patients who have not previously used anti-obesity medications may achieve better weight loss results with semaglutide.

Nutrition periodization is crucial for optimal performance and body composition in football players.

Coaches and nutritionists should tailor diets to training phases for better performance.

Increased protein and energy intake is recommended during the preparatory phase to support muscle mass development.

Increase protein and energy intake during the preparatory phase for muscle development.

Carbohydrates are emphasized for glycogen replenishment and recovery during the competitive period.

Focus on carbohydrate intake during competitive phases for optimal recovery.

Semaglutide treatment led to a weight decrease of 16 kg and a 36% reduction in insulin dose after 6 months in a patient with type 1 diabetes.

Semaglutide may be a beneficial treatment option for weight management in patients with type 1 diabetes.

Tirzepatide effectively reduces glucose levels and body weight in patients with type 2 diabetes and/or obesity.

Clinicians can consider tirzepatide as a treatment option for managing glucose levels and weight in these patients.

Tirzepatide (TZP) offers superior efficacy in reducing glycemic levels and body weight compared to existing therapies.

Practitioners may consider TZP as a more effective treatment option for patients struggling to achieve glycemic control and weight loss.

Resistance training increased fat-free mass (FFM) and strength gains similarly in the three groups.

Resistance training is effective for increasing muscle mass and strength regardless of protein supplementation.

Fat-free mass (FFM) increased by 2.3% in the whey protein group, 3.6% in the chia flour group, and 3.0% in the placebo group.

The study provides specific data on how much FFM increased in each group, which can inform future research and practice.

UPFs increase the risk of chronic diseases and death.

Public health initiatives should address the risks associated with UPF consumption.

A 3-month regimen of nutrition counseling and high-intensity resistance training resulted in a 6.6% reduction in body fat and a 1.4% increase in muscle mass.

Practitioners can implement similar exercise and nutrition regimens to promote fat loss and muscle gain in breast cancer patients.

Participants demonstrated a 36.5% increase in composite load lifted across compound exercises.

Strength training protocols can effectively enhance lifting capacity in breast cancer survivors.

At 1-month follow-up, patients showed a 22.3 percent decrease in average fat tissue and a 21.5 percent increase in muscle mass.

The HIFEM+RF procedure can effectively reduce fat and increase muscle in the upper arms.